Efficacy News and Research

RSS
Celldex Therapeutics reports net loss of $13.5M for fourth-quarter of 2009

Celldex Therapeutics reports net loss of $13.5M for fourth-quarter of 2009

Covidien enters into preferred vendor partnership with OSF Healthcare System

Covidien enters into preferred vendor partnership with OSF Healthcare System

Boosting immune response to vaccinations: Role of aluminium adjuvants

Boosting immune response to vaccinations: Role of aluminium adjuvants

Macroplastique effective for stress urinary incontinence in women

Macroplastique effective for stress urinary incontinence in women

Childhood absence epilepsy: Comparative clinical trial of widely used anti-seizure drugs

Childhood absence epilepsy: Comparative clinical trial of widely used anti-seizure drugs

ReShape Medical initiates IDE clinical study to assess effectiveness of dual-balloon device for weight loss

ReShape Medical initiates IDE clinical study to assess effectiveness of dual-balloon device for weight loss

Data from FAME Phase 3 study for Iluvien presented at Angiogenesis 2010

Data from FAME Phase 3 study for Iluvien presented at Angiogenesis 2010

Gene therapy for LCA clears another hurdle: Study

Gene therapy for LCA clears another hurdle: Study

Belatacept drug can prevent graft rejection in kidney transplant recipients

Belatacept drug can prevent graft rejection in kidney transplant recipients

Study: Salvage targeted therapy can be suitable for elderly patients with NSCLC

Study: Salvage targeted therapy can be suitable for elderly patients with NSCLC

New chemical classes of preclinical compounds identified for Alzheimer’s disease

New chemical classes of preclinical compounds identified for Alzheimer’s disease

Zoraxel for treatment of ED: Rexahn Pharmaceuticals submits Phase IIb protocol to FDA

Zoraxel for treatment of ED: Rexahn Pharmaceuticals submits Phase IIb protocol to FDA

CPEX Pharmaceuticals' fourth-quarter 2009 revenues up 23%

CPEX Pharmaceuticals' fourth-quarter 2009 revenues up 23%

Actemra: 38% of rheumatologists have commenced treatment

Actemra: 38% of rheumatologists have commenced treatment

Pfizer, Medivation announce results of two dimebon Phase 3 trials in AD patients

Pfizer, Medivation announce results of two dimebon Phase 3 trials in AD patients

Spectral Diagnostics receives FDA IDE approval for Toraymyxin

Spectral Diagnostics receives FDA IDE approval for Toraymyxin

Allergan celebrates 20th anniversary of BOTOX in Canada

Allergan celebrates 20th anniversary of BOTOX in Canada

Positive clinical trial results of EndoBarrier Gastrointestinal Liner device announced

Positive clinical trial results of EndoBarrier Gastrointestinal Liner device announced

"Stem cells in drug discovery and development" workshop to be held during toxicology annual meeting

"Stem cells in drug discovery and development" workshop to be held during toxicology annual meeting

Merck’s MF/F Phase III study data presented at AAAAI annual meeting

Merck’s MF/F Phase III study data presented at AAAAI annual meeting

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.